Skip to Content
  • Tracked for
    Impact Factor
  • 1.2
    CiteScore
  • 22 days
    Submission to First Decision
  • 7 days
    Acceptance to Publication

Transplantology

Transplantology is an international, peer-reviewed, open access journal on all areas of experimental and clinical transplantation, published quarterly online by MDPI.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (205)

  • Case Report
  • Open Access

Background: Rhino-orbital mucormycosis is a rapidly progressive opportunistic infection in immunocompromised patients. Early disease may lack characteristic sinonasal findings, which can delay tissue diagnosis. Case Presentation: A 29-year-old man with focal segmental glomerulosclerosis underwent living-donor kidney transplantation in October 2024. He received tacrolimus, mycophenolate mofetil, and corticosteroids. In February 2025, he was admitted with fever, chills, headache, and febrile neutropenia. Initial otorhinolaryngologic examination and paranasal sinus computed tomography showed no findings suggestive of mucormycosis. His prolonged hospital course was complicated by recurrent fever, pancytopenia, and multiple microbiological findings, including Candida krusei, Aspergillus flavus, cytomegalovirus, and adenovirus. When a new crusted lesion developed in the oral cavity and nasal passage, punch biopsy with intraoperative frozen-section assessment demonstrated mucormycosis. Surgical debridement and liposomal amphotericin B at 5 mg/kg/day were initiated, and immunosuppression was reduced. Subsequent contrast-enhanced magnetic resonance imaging demonstrated nasopharyngeal, orbital, and sinonasal involvement. Despite intensive antifungal therapy, surgery, and supportive care, the patient died during hospitalization. Conclusions: Initially normal sinonasal examination and imaging do not exclude mucormycosis in highly immunosuppressed kidney transplant recipients. Repeated examination and urgent tissue sampling are essential when fever persists without a satisfactory response to antimicrobial treatment.

Transplantology

12 November 2026

Clinical and histopathological findings. (A) Intraoral mucosal lesion observed during the clinical course. (B) Representative histopathological image showing fungal elements consistent with mucormycosis.
  • Case Report
  • Open Access

Acute myeloid leukemia with minimal differentiation (AML-M0) is a clinically rare high-risk subtype of acute myeloid leukemia. Tumor cells of this subtype have an extremely low degree of differentiation, making morphological identification challenging. It is characterized by high overall malignancy, frequent primary drug resistance and a high recurrence rate, leading to extremely poor long-term prognosis in pediatric patients. Currently, there is no unified standard salvage treatment regimen for this condition. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a critical curative approach for high-risk acute myeloid leukemia. Nevertheless, some pediatric patients still experience disease relapse after multi-line chemotherapy and initial transplantation. Conventional salvage chemotherapy yields a low re-remission rate and short remission duration, which remains a major focus and challenge in clinical management. Selinexor, a novel oral selective inhibitor of exportin 1 (XPO1), exerts anti-leukemic effects by reversing tumor drug resistance and promoting apoptosis of leukemic cells, showing promising application prospects in relapsed/refractory acute myeloid leukemia. This article reports an 8-year-old pediatric patient with AML-M0, who suffered multiple relapses following conventional multi-regimen chemotherapy and the first haploidentical donor (father) allo-HSCT, and developed resistance to multi-line salvage chemotherapy. Salvage therapy with selinexor combined with chemotherapy was administered at our center as a desperation measure in this ultra-high-risk setting after all standard curative options had been exhausted. The patient achieved deep complete remission again and was successfully bridged to a second allo-HSCT; as of the last follow-up, the patient remained in continuous complete remission, although the observation period after the second (April 2026) transplantation is still limited. Given the absence of prospective safety data for this specific four-drug combination—particularly in a child with pre-existing pulmonary chronic GVHD and impaired ventilatory function—potential uncharacterized synergistic toxicities must be emphasized, and this experience should be interpreted strictly as a single-case desperation measure that cannot be recommended or generalized without formal clinical trials. Combined with the diagnosis and treatment course of this case and relevant domestic and international literature, this paper discusses the potential clinical efficacy, medication safety and application value of selinexor in pediatric patients with relapsed/refractory acute myeloid leukemia after transplantation. We emphasize that this four-drug regimen constituted a desperation measure in an ultra-high-risk setting with no remaining standard curative options, that it carries unknown synergistic toxicities, and that it cannot be recommended or generalized without formal prospective clinical trials, although it may provide a reference for individualized treatment of comparable high-risk pediatric patients after multidisciplinary evaluation.

Transplantology

9 November 2026

  • Review
  • Open Access

Lung Transplantation in Pulmonary Arterial Hypertension: A Review

  • Zehra Dhanani,
  • Jenny Yang and
  • Kamyar Afshar
  • + 1 author

Lung transplantation remains a key treatment option for patients with pulmonary arterial hypertension (PAH) who continue to deteriorate despite targeted medical therapy. However, lung transplant remains underutilized in PAH, and these patients have among the highest waitlist mortality of any transplant indication. This narrative review, based on a PubMed search and author selection of the literature, synthesizes evidence on indications for lung transplant referral in PAH, risk stratification scores that provide insight into disease status, and the evolving medical therapies for PAH, including sotatercept, and their potential impact on referral and transplant practice. We then review preoperative and perioperative strategies for PAH patients, including hemodynamic support, primary graft dysfunction, extracorporeal membrane oxygenation, and the choice between bilateral lung and heart–lung transplantation, along with post-transplant outcomes. We also review geographic and institutional differences in organ availability and outcomes that may affect patients with PAH. Our findings suggest a need for earlier referral, research on how newer medications will affect referral and outcomes, and standardization of surgical and systemic practices to achieve good outcomes in this unique population.

Transplantology

5 November 2026

  • Case Report
  • Open Access

Nocardia is an opportunistic pathogen associated with life-threatening infections, particularly in solid organ transplant recipients. In this population, combination therapy with two or more antibiotics and prolonged treatment duration are generally recommended to minimize the risk of relapse, although tolerability issues may adversely affect clinical outcomes. Herein, we present two cases of Nocardia infection in heart transplant recipients treated with short-term treatment (<180 days), including tedizolid. This treatment was effective in treating pulmonary nocardiosis in a heart transplant recipient, while remodulation of the immunosuppressive regimen to restore immune function with a longer course of antimicrobial therapy (7 months) contributed to successful treatment in the second case. These two cases are anecdotal, and there are currently only a few case series reported in the literature to support recommending a short course of treatment for Nocardia infection in SOT recipients. Nevertheless, the occurrence of adverse effects or tolerability issues during prolonged treatment may make a shorter treatment approach an interesting option to explore.

Transplantology

29 October 2026

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Transplantology - ISSN 2673-3943